33.20USD+2.25%Mkt Cap: 1.99B USDP/E: —Last update: 2026-05-26
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platfo…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.99B USD
Enterprise Value1.59B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-119.95M USD
Revenue/Share—
Last Price33.20 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees87
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.64
PEG—
EV/EBITDA-11.14
EV/Revenue—
P/S—
P/B6.84
EPS (TTM)-2.18
EPS (Forward)-2.84
52W Range
8.75077% of range40.65
52W High40.65 USD
52W Low8.750 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-46.28%
ROA-42.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-95.14M USD
CapEx (TTM)141.00K USD
FCF Margin—
FCF Yield-3.02%
Net Debt-377.77M USD
Net Debt/EBITDA2.65
Balance Sheet
Debt/Equity0.02
Current Ratio20.49
Quick Ratio20.05
Book Value/Sh4.826 USD
Cash/Share6.448 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)51.15 USD
Target Range37.00 USD – 59.62 USD
# Analysts11
Ownership
Shares Out.59.47M
Float30.93M
Insiders2.86%
Institutions111.39%
Short Interest
Short Ratio6.8d
Short % Float23.95%
Short % Out.12.96%
Shares Short7.71M
Short (prev mo.)8.26M
Technical
SMA 5035.99 (-7.7%)
SMA 20024.49 (+35.6%)
Beta0.79
S&P 52W Chg28.31%
Avg Vol (30d)890.26K
Avg Vol (10d)759.82K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—